GT Biopharma Inc (LTS:0RU9)
€ 1147194 0 (0%) Market Cap: 5.92 Mil Enterprise Value: -3.33 Mil PE Ratio: 0 PB Ratio: 2.99 GF Score: 34/100

GT Biopharma Inc at HC Wainwright Cell Therapy Virtual Conference Transcript

Feb 28, 2023 / 02:00PM GMT
Release Date Price: €1147194
Robert Burns
H.C. Wainwright & Co., LLC - Analyst

Welcome to our next presentation. I'm Robert Burns, a Managing Director and Senior Biotech Analyst at H.C. Wainwright. I'm joined today by Michael Breen, the CEO of GT Biopharma; and Dr. Jeffrey Miller, the consulting CMO and CSO of GT Biopharma. With that said, Dr. Miller, take it away.

Jeffrey Miller
GT Biopharma, Inc. - Consulting Chief Medical Officer and Chief Scientific Officer

Great. Thank you very much. So today, I'm going to talk a little bit about our tri-specific NK cell engagers, or TriKEs, as we refer to them. Here's our forward-looking statement. So as a very brief introduction, what we have developed here is a camelid nanobody TriKE platform.

The importance of these NK cell engagers is a couple of things, and we'll get through this as I go through the data. But I wanted people to realize that these are protein engagers. And these are not cell therapies, which are very, very different. The thing that's very unique about our platform is that on the NK cell side, we engage two

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot